Contraceptive Patch
From
the Billings Gazette
Stats
indicate contraceptive patch may be riskier than pill
Associated
Press
Gingerly,
Kathleen Thoren's family gathered around her in the intensive care unit, unable
to speak to their beloved sister, daughter, wife, or even stroke her hands. The
slightest stimulation might create a fatal amount of pressure on the
25-year-old woman's swollen brain, warned the doctors.
"We
were horrified, but we tried to just quietly be with her," said her sister
Erika Klein. "In the end, it didn't help."
The
Wyoming mother of three died last fall, just after Thanksgiving, after days of
agonizing headaches that the coroner's report said were brought on by hormones
released into her system by Ortho Evra, a birth control patch she had started
using a few weeks earlier.
She
was among about a dozen women, most in their late teens and early 20s, who died
last year from blood clots believed to be related to the birth control patch.
Dozens more survived strokes and other clot-related problems, according to
federal drug safety reports obtained by The Associated Press under a Freedom of
Information Act request.
Several
lawsuits have already been filed by families of women who died or suffered blood
clots while using the patch, and lawyers said more are planned.
FDA,
firm call patch safe
Though
the Food and Drug Administration and patch-maker Ortho McNeil saw warning signs
of possible problems with the patch well before it reached the market, both
maintain that the patch is as safe as the pill.
However,
the reports obtained by the AP appear to indicate that in 2004 - when 800,000
women were on the patch - the risk of dying or suffering a survivable blood clot
while using the device was about three times higher than while using birth
control pills.
The
women who died were young and apparently at low risk for clots - women like
Zakiya Kennedy, an 18-year-old Manhattan fashion student who collapsed and died
in a New York subway station last April. Or Sasha Webber, a 25-year-old mother
of two from Baychester, N.Y., who died of a heart attack after six weeks on the
patch last March.
Some
doctors, reviewing the Food and Drug Administration reports at the request of
The AP, were alarmed. "I was shocked," said Dr. Alan DeCherney,
editor in chief of Fertility and Sterility and a UCLA professor of obstetrics
and gynecology.
But
other doctors said they would have expected some deaths and no investigation is
warranted. They point to more than 4 million women who have safely used the
patch and note that the FDA reports are called in voluntarily, rather than
gathered scientifically.
"It
doesn't jump out at me to say, 'Let's look at this any further,' " agreed
Dr. Steven J. Sondheimer, professor of obstetrics and gynecology at the
University of Pennsylvania. "I don't feel that these need to be looked at
in any detail."
Ortho
McNeil, a subsidiary of Johnson & Johnson, says none of the deaths can be
directly attributed to the patch.
"Although
we are investigating each and every one of the reports that we get, we have not
drawn any causal relationships to the medication," said Dr. Katherine
LaGuardia, Ortho McNeil's director of women's health care.
Not
one? "Right," she said. "It's difficult to reach a definitive
answer, and privacy laws prevent us from investigating as thoroughly as we
wish."
Clots
are accepted risk
Blood
clots are an accepted risk from hormonal birth control because estrogen
promotes blood coagulation.
But
how many clots are too many?
The
AP found that before the patch was approved, the FDA had already noticed
nonfatal blood clots from the patch were three times that of the pill. The AP
then examined what has actually happened since the patch came on the market and
found that deaths also appear to be at least three times as high.
If
you are a woman taking the pill who doesn't smoke and is under 35, the chance
that you are going to have a blood clot that doesn't kill you is between 1 and
3 in 10,000. Your risk of dying from a blood clot while using the pill is about
1 in 200,000.
By
contrast, with the patch, the rate of nonfatal blood clots was about 12 out of
10,000 users during the clinical trials, while the rate of deaths appears to be
3 out of 200,000.
Clots
usually form in the legs, and become serious problems if they travel to a
woman's heart, lungs or brain.
In
2000, doctors at the FDA reviewing clinical trials of the wafer-thin, plastic
patch warned that blood clots could be a problem if it was approved.
In
those trials, two of the 3,300 women using the patch were treated for blood
clots that traveled to their lungs. Ortho McNeil says one of those women
shouldn't be counted because she had undergone surgery. But an FDA reviewer, using
capital letters and underscoring his comments, took issue with Ortho McNeil.
"THE
REVIEWER DOES NOT AGREE WITH THE SPONSOR'S ABOVE CONCLUSIONS. The two cases of
pulmonary embolus, a serious and potentially fatal condition, must be counted
as two cases ... ," said the report. "The incidence rates quoted by
the sponsor may be misleading."
The
reviewer said that "the label should clearly reflect this reviewer's
safety concern about a potential increased risk." It would be important to
study users after the patch came on the market for clot problems, he wrote.
But
when the patch was approved in the U.S. in 2001, there were no requirements for
follow-up studies beyond routine FDA reviews of reports called in by consumers,
doctors and manufacturers.
The
label's safety warning says two different and seemingly contradictory things:
First, it says the patch is expected to
be associated with similar risks as the pill.
Then, it says it is unknown if the risk
of blood clots from the patch is different from the pill.
The
AP reviewed what has happened since the patch came on the market in 2002.
The
FDA responded to a FOIA request by providing the AP with a database that
contained about 16,000 different reports of adverse reactions associated with
the patch.
These
ranged from mild rashes to deaths, and there were many duplicate reports.
Within this collection of reports, the AP found 23 different deaths associated
with the patch. The primary cause of death in those reports isn't always clear
- some mention suicide, others abortion. Doctors who reviewed the 23 cases
found about 17 that appeared to be clot-related, including 12 from last year.
"That
number of deaths certainly sounds suspicious," said Dr. Pamela Berens,
associate professor of obstetrics and gynecology at the University of Texas
Medical School at Houston. "There may be something about the way the drug
is metabolized that could increase the risk for clots."
Different
processing
Although
the estrogen levels are similar in the patch and the pill, the hormones in a
pill must be processed through the intestinal tract before they enter the
bloodstream. Hormones in the patch, on the other hand, go directly into the
bloodstream.
Dr.
Sidney Wolfe, director of Public Citizen's Health Research Group, a consumer
advocacy organization founded by Ralph Nader, said that the deaths and high
rate of clots are "worrisome" and should be investigated.
"These
days, more often than not the problems with a drug show up after they're
approved," he said.
But
Dr. Daniel Shames, the FDA's director of the Division of Reproductive and
Urological Drug Products, who approved the agency's medical review, said he has
reviewed cases of women who died using the patch and saw no cause for alarm.
"We
think the death rate here is of concern, but it's not different than what we
expect," he said. "As of right now we still believe there's nothing
that would precipitate our doing anything additional to follow up on these
reports."
And
other doctors who prescribe the patch warned that women should not overreact to
news of deaths. It is more risky to remove the patch and become pregnant,
several pointed out.
Dr.
Philip Darney, a professor of obstetrics and gynecology at the University of
California, San Francisco, and a leading contraceptive researcher, cautioned
that the FDA's adverse event reports tend to be inflated for newer products
like the patch.
Patients
and doctors are more likely to contact the FDA when they have a bad reaction to
a new drug than for something that has been on the market for a long time, he
said. In addition, women using the patch are likely to either be new to
hormonal birth control or have reacted poorly to the pill and are looking for a
change. The result is that the pool of women using the patch are at higher risk
than birth control users at large.
He
tells patients, "If you can use a pill safely, you can use a patch safely,
and we're going to know a lot more later as more women use patches," he
said.
Ortho
McNeil recommended that the AP speak to two doctors, Dr. Hilda Hutcherson,
co-director of the NY Center for Women's Sexual Health and a professor at
Columbia University Medical Center, and Dr. Vanessa Cullins, vice president of
medical affairs at Planned Parenthood Federation of America. Both doctors have served
in the past as paid advisers to Ortho McNeil.
Hutcherson
said the risks of blood clots from hormones are well known, and that "what
has happened with the patch is consistent."
Cullins
said she did her own comparison of data for the pill and patch and found the
patch is safer than expected.
"My
research was to determine whether or not the expected number of deaths from the
pill was lower than what was seen with the number of deaths reported with Ortho
Evra. I found the opposite," said Cullins, who has done research,
consulted for and been a speaker for Ortho McNeil and other drug companies.
Cullins
said she reviewed the deaths looking at "women years" rather than
current users. Women years is a measure that takes into account that different
people use a particular contraceptive for different periods of time. For
example, if three women each used a patch for four months, that would count as
one woman year rather than three current users.
Cullins
reviewed patch users from 2002, when the patch came on the market, until late
2003. For that period, Cullins said she would have expected 22 deaths and found
only 6.
The
AP reviewed the deaths looking at both women years and current users, but used
more recent data, focusing on 2004 when the patch had been much more widely
adopted.
Copyright
© 2005 Associated Press. All rights reserved. This material may not be
published, broadcast, rewritten, or redistributed.
Copyright
© The Billings Gazette, a division of Lee Enterprises.
Home * Hair Analysis * Saunas * Books * Articles
Detoxification Protocols
* Courses * About Dr. Wilson